UK Pharmacist: Blue Inhalers Are a Red Flag

More than seven million people in the UK are living with asthma, with a recent warning highlighting a significant concern regarding the use of blue inhalers. Pharmacists are now identifying the frequent reliance on these reliever inhalers as a serious red flag for individuals with the condition.

These blue inhalers, containing salbutamol, offer rapid relief for breathing difficulties. However, they do not address the underlying inflammation characteristic of asthma. This means that while symptoms may temporarily subside, the condition could be deteriorating unnoticed.

Updated guidance from NICE indicates that overuse of blue inhalers is associated with an increased risk of asthma attacks, hospital admissions, and mortality. The current recommendations advocate for a shift towards combination inhalers.

These advanced treatments combine an inhaled steroid with a long-acting beta2 agonist, such as formoterol, in a single device. They are designed to manage inflammation and prevent flare-ups, offering a more comprehensive approach to asthma control than reliever inhalers alone.

Figures from England show that almost half of all blue inhaler users were prescribed more than two within the 2024-2025 period, a statistic specialists consider a worrying indicator. This trend underscores the urgent need for patients to consult with their doctors about alternative, more effective treatment strategies.

Individuals experiencing frequent reliance on their blue inhaler should speak to their healthcare provider about transitioning to a combination inhaler. This ensures both symptom relief and effective management of the underlying inflammatory processes of asthma.